Early assessment of IL8 and PD1+ Treg predicts response and guides treatment monitoring in cemiplimab-treated cutaneous squamous cell carcinoma

Purpose Anti-programmed cell death 1 (PD1) is the first-choice treatment in patients with advanced cutaneous squamous cell carcinoma (cSCC), when curative options are unavailable. However, reliable biomarkers for patient selection are still lacking.Experimental design In this translational study, cl...

Full description

Saved in:

Bibliographic Details
Main Authors:	Teresa Troiani, Fabiana Napolitano, Luigi Formisano, Roberto Bianco, Daniela Russo, Daniela Esposito, Giuseppe Ercolano, Angela Ianaro, Alberto Servetto, Daniela Claudia Maresca, Marcella Scala, Annarita Amato, Stefania Belli, Claudia Maria Ascione, Angela Vallefuoco, Giovanna Attanasio, Fabio Somma, Silvia Varricchio, Massimo Mascolo, Claudia Costa, Alessia Villani, Massimiliano Scalvenzi, Gianfranco Orlandino
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-01-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/1/e010421.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Early assessment of IL8 and PD1+ Treg predicts response and guides treatment monitoring in cemiplimab-treated cutaneous squamous cell carcinoma

Similar Items